Subject: new article - "Hepatitis B Core Antibody: Role in Clinical Practice in 2020"
From: Robert Gish <[email-masked]>
To: Undisclosed recipients:Undisclosed
Date: Mon, 13 Jul 2020 15:51:50 +0000

Thank you all for input from colleagues in the hepatology community to help update all providers on the facts about anti-HBc.

You can read the newly published article here:

https://rdcu.be/b5zpZ

2 key take-away points

False + rate for current anti-HBc testing is 2/1,000

Anti-HBc + (total) test = cccDNA

Risk for reactivation

No need for HBV vaccine

Consider evaluation for OBI in clinical setting of anti-HBc alone

There is no current peer reviewed data that patients clear cccDNA after acute HBV and total anti-HBc+ tracks the presence of cccDNA

Cautious use of anti-HBc IgM use in clinical practice to diagnose and manage “acute HBV”

Thank you,

Robert G. Gish MD

+1 858 229 9865